KFA
BMY icon

Krane Funds Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Krane Funds Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$609K Buy
10,571
+1,040
+11% +$59.7K 0.02% 120
2026
Q1 		$563K Buy
9,531
+2,157
+29% +$126K 0.02% 116
2025
Q4 		$398K Sell
7,374
-1,679
-19% -$80.8K 0.01% 123
2025
Q3 		$392K Sell
9,053
-396
-4% -$18.5K 0.01% 112
2025
Q2 		$437K Buy
9,449
+1,359
+17% +$66.7K 0.02% 76
2025
Q1 		$493K Sell
8,090
-998
-11% -$58.2K 0.01% 50
2024
Q4 		$514K Sell
9,088
-1,665
-15% -$93K 0.02% 39
2024
Q3 		$556K Buy
10,753
+829
+8% +$38.9K 0.02% 41
2024
Q2 		$412K Sell
9,924
-502
-5% -$22.5K 0.02% 62
2024
Q1 		$550K Buy
10,426
+5,038
+94% +$257K 0.02% 40
2023
Q4 		$276K Sell
5,388
-4,330
-45% -$227K 0.01% 87
2023
Q3 		$564K Buy
9,718
+795
+9% +$48.7K 0.02% 47
2023
Q2 		$571K Buy
8,923
+228
+3% +$15.3K 0.03% 45
2023
Q1 		$609K Sell
8,695
-183
-2% -$12.9K 0.03% 50
2022
Q4 		$639K Sell
8,878
-1,489
-14% -$112K 0.03% 44
2022
Q3 		$737K Sell
10,367
-110
-1% -$7.98K 0.04% 51
2022
Q2 		$807K Sell
10,477
-3,112
-23% -$237K 0.03% 58
2022
Q1 		$992K Buy
13,589
+7,143
+111% +$480K 0.04% 62
2021
Q4 		$402K Sell
6,446
-814
-11% -$47.8K 0.01% 174
2021
Q3 		$430K Sell
7,260
-10,436
-59% -$687K 0.01% 171
2021
Q2 		$1.18M Buy
17,696
+11,701
+195% +$763K 0.04% 67
2021
Q1 		$378K Sell
5,995
-4,574
-43% -$285K 0.01% 263
2020
Q4 		$656K Buy
10,569
+4,080
+63% +$251K 0.03% 118
2020
Q3 		$391K Sell
6,489
-158
-2% -$9.51K 0.02% 138
2020
Q2 		$391K Sell
6,647
-1,472
-18% -$88K 0.02% 120
2020
Q1 		$453K Sell
8,119
-763
-9% -$46.6K 0.02% 107
2019
Q4 		$570K Buy
+8,882
New +$509K 0.04% 93

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Krane Funds Advisors's BMY Position: Q2 2026 in Review

Krane Funds Advisors increased its Bristol-Myers Squibb (BMY) stake by 11% in Q2 2026, buying an estimated $59.7K and bringing the position to 10,571 shares worth $609K. The position accounts for 0.02% of the portfolio, ranked #120.

Krane Funds Advisors first reported a position in BMY in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.18M in Q2 2021. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Krane Funds Advisors held 10,571 shares of Bristol-Myers Squibb worth $609K as of Q2 2026.
  • Krane Funds Advisors bought 1,040 Bristol-Myers Squibb shares in Q2 2026, an estimated $59.7K.
  • Bristol-Myers Squibb made up 0.02% of Krane Funds Advisors's portfolio in Q2 2026, its #120 holding.
  • Krane Funds Advisors first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 27 quarters since.
  • Krane Funds Advisors's Bristol-Myers Squibb position peaked at $1.18M in Q2 2021.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Krane Funds Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.